Mebelin

Mebeverine Hydrochloride, the active ingredient in Mebelin, is an antispasmodic (smooth muscle relaxant) presented as an oral tablet for oral use. It is employed to relieve gastrointestinal spasm and associated pain in adults with functional bowel conditions. GNH USA supplies Mebelin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mebeverine Hydrochloride acts on smooth muscle of the gastrointestinal tract to alleviate spasm and discomfort. - Irritable bowel syndrome (IBS): reduces abdominal pain and irregular bowel habits. - Functional bowel disorders: eases cramping and improves bowel regularity. - Colicky abdominal pain: diminishes spasm‑related discomfort in acute episodes.

Mebeverine is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Dry mouth: reduced salivation. - Headache: transient cranial discomfort. - Dizziness: occasional light‑headedness. - Abdominal cramps: brief episodes of discomfort. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Allergic reaction: rash, itching, or swelling. - Severe skin eruption: Stevens‑Johnson‑type rash. - Angioedema: swelling of face, lips, or throat. - Hepatic dysfunction: abnormal liver enzymes. - Cardiac arrhythmia: irregular heartbeat in susceptible patients.

Before prescribing Mebelin, clinicians should consider several safety aspects. - Assess renal and hepatic function: adjust use if impairment is present. - Avoid in known hypersensitivity: discontinue if allergic signs appear. - Use caution in the elderly: monitor for increased sensitivity to side effects. - Review concomitant anticholinergic medications: risk of additive dry‑mouth or constipation. - Monitor for persistent constipation or severe abdominal pain. - Store at ambient temperature: keep in the original pack, protect from moisture.

Mebeverine may interact with other medicines, requiring attention to the level of risk.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase mebeverine exposure. - Concurrent smooth‑muscle relaxants: additive antispasmodic effect. - Anticholinergic agents: heightened anticholinergic burden.

Moderate Interactions (Monitor Closely): - Antacids: may alter gastrointestinal pH and affect absorption. - Grapefruit juice: potential to modestly raise plasma levels. - Diuretics: monitor electrolytes if combined with extensive fluid loss.